State Street Corp Buys 58,838 Shares of INmune Bio, Inc. (NASDAQ:INMB)

State Street Corp increased its stake in INmune Bio, Inc. (NASDAQ:INMB) by 35.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 226,428 shares of the company’s stock after purchasing an additional 58,838 shares during the quarter. State Street Corp owned approximately 1.02% of INmune Bio worth $1,220,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in INMB. Bank of New York Mellon Corp raised its position in shares of INmune Bio by 124.6% in the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after purchasing an additional 32,511 shares during the period. Rhumbline Advisers acquired a new position in INmune Bio in the 2nd quarter valued at $121,000. Marshall Wace LLP raised its holdings in INmune Bio by 332.1% in the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after acquiring an additional 89,091 shares during the period. CVI Holdings LLC acquired a new position in INmune Bio during the 2nd quarter worth $5,260,000. Finally, Fermata Advisors LLC boosted its holdings in INmune Bio by 25.2% during the third quarter. Fermata Advisors LLC now owns 42,730 shares of the company’s stock valued at $230,000 after acquiring an additional 8,590 shares during the period. Institutional investors own 12.72% of the company’s stock.

INmune Bio Stock Up 5.6 %

INMB stock opened at $4.93 on Friday. INmune Bio, Inc. has a twelve month low of $4.32 and a twelve month high of $14.74. The company has a market cap of $109.31 million, a PE ratio of -2.26 and a beta of 1.79. The business’s 50-day simple moving average is $5.19 and its 200 day simple moving average is $6.25.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.59%. During the same period in the prior year, the company posted ($0.48) earnings per share. On average, equities research analysts anticipate that INmune Bio, Inc. will post -2.24 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Alliance Global Partners assumed coverage on INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 price objective on the stock. Raymond James initiated coverage on INmune Bio in a research report on Friday, September 27th. They issued an “outperform” rating and a $18.00 price target on the stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.